<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618384</url>
  </required_header>
  <id_info>
    <org_study_id>SOCRATES-072</org_study_id>
    <nct_id>NCT00618384</nct_id>
  </id_info>
  <brief_title>TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <acronym>SOCRATES</acronym>
  <official_title>Phase II Study Evaluating Transarterial Chemoembolization (TACE) in Combination With Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with advanced HCC not suitable for resection or liver transplantation but
      without extrahepatic manifestations, local therapy with TACE is regarded as standard
      treatment. The present study is planned to evaluate the combination of TACE and sorafenib. A
      combination of TACE with a multitarget inhibitor like sorafenib may further improve the
      outcome of patients with HCC.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determination of time to progression (TTP)</measure>
    <time_frame>every 30 days after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>3-week-periods</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with TACE therapy will be treated with Sorafenib (2 x 400 mg/day) until progressive disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  with histologically confirmed HCC not suitable for resection or liver transplantation

          -  Patients with measurable disease according to RECIST

          -  Performance status ECOG 0-2

          -  Normal organ and bone marrow function (defined)

          -  Women of childbearing potential must have performed a negative serum pregnancy test

          -  male or female patients must use an approved contraceptive method during treatment and
             for 3 months after end of treatment after the end of treatment with study medication

          -  Written informed consent

        Exclusion Criteria:

          -  Patient is eligible for liver resection or liver transplantation

          -  Extrahepatic tumor manifestation

          -  Thrombosis of the portal vein

          -  &gt; 8 points according to Child Pugh classification

          -  Prior TACE or RFTA or any other local ablative treatment

          -  Prior systemic anticancer chemotherapy or radiotherapy for HCC

          -  Total bilirubin &gt; 4.5 mg/dl

          -  Life expectancy of less than 12 weeks

          -  Esophageal varices grade III without prophylactic band ligation

          -  Cardiac diseases (defined)

          -  Uncontrolled hypertension

          -  Known or suspected hyperthyroid state

          -  Known brain metastasis

          -  Patients with seizure disorder requiring medication

          -  History of organ allograft

          -  Active clinically serious infections &gt; CTCAE grade 2

          -  Thrombotic or embolic events

          -  Hemorrhage/bleeding event (defined)

          -  Acute variceal bleeding

          -  Therapeutic anticoagulation with vitamin K antagonists (defined)

          -  Known or suspected allergies to sorafenib, doxorubicin or lipiodol or any agent given
             in the course of this trial

          -  Contraindications to the use of sorafenib, doxorubicin or lipiodol

          -  Previous cancer distinct in primary site or histology from HCC (defined)

          -  substance abuse

          -  Participation in another clinical trial with any investigational study drug

          -  Lactating women

          -  Incapability to give valid informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Erhardt, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastroenterology, Hepatology and Infectiology University Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen Innere Medizin I</name>
      <address>
        <city>Tübingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Ulm Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <state>BW</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Großhardern</name>
      <address>
        <city>Muenchen</city>
        <state>BY</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <state>HE</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Zentrum für Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <state>HH</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität Medizinische Klinik</name>
      <address>
        <city>Mainz</city>
        <state>RP</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TACE</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

